Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
How to invest
5 Warren Buffett quotes to become a better ASX share investor
Share Market News
5 'particularly interesting' ASX All Ords stocks to buy amid the Trump tariff mayhem
How to invest
Why this ASX share market selloff could be a golden opportunity for investors
Healthcare Shares
Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare
Blue Chip Shares
3 leading ASX 200 blue chip shares to buy after the market selloff
Blue Chip Shares
3 unstoppable ASX 200 stocks to buy and hold forever
Broker Notes
'This is a great time to get rich': 3 of the best ASX shares to buy
Healthcare Shares
How are Cochlear shares impacted by Trump's tariffs?
Blue Chip Shares
Where to invest $10,000 into ASX 200 shares in April
Share Market News
5 things to watch on the ASX 200 on Thursday
Blue Chip Shares
These blue chip ASX 200 stocks could rise 12% to 35%
How to invest
Why I think ASX 200 shares remain the best path to long-term wealth
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
